BRAF and familial atrioventricular septal defect: A trial of vemurafenib, a specific inhibitor of mutant BRAF resulted in substantial clinical improvement in three patients with ECD and Langerhans cell histiocytosis [16] offering a novel and effective therapeutic option for these severe disorders.